Aileron Therapeutics | Date: 2014-09-26
Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.
Aileron Therapeutics | Date: 2015-09-24
Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
Aileron Therapeutics | Date: 2015-01-29
Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
Aileron Therapeutics | Date: 2015-05-21
The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Aileron Therapeutics | Date: 2015-09-14
The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.